The Offering will begin immediately and will be completed through an accelerated book-building process in a private placement directed at qualified institutional and professional investors in Denmark and certain other jurisdictions. Use of proceeds and background of the Offering On 7 July 2023, Coloplast announced an agreement to acquire Kerecis, an innovative, fast-growing company in the biologics wound care segment, for a consideration of up to USD 1.3 billion (around DKK 8.9 billion*), of which USD 1.2 billion (around DKK 8.2 billion*) is an upfront cash payment (the " Transaction "). The Transaction is expected to close on 31 August 2023, as all regulatory approvals have been received and more than 99% of Kerecis' existing shareholders have committed to sell their shares in Kerecis to Coloplast. The net proceeds from completion of the Offering are intended to be used for payment of the purchase price in respect of the Transaction.